Patents by Inventor Miroslav MATEV

Miroslav MATEV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11512135
    Abstract: Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 29, 2022
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Yuri Koshimura, Hiroyuki Sonoda, Miroslav Matev, Shinji Kakimoto, Tsuyoshi Fukui, Yukichi Hatano
  • Patent number: 10858640
    Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 8, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
  • Patent number: 10604779
    Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: March 31, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Shinji Kakimoto, Miroslav Matev, Tsuyoshi Fukui, Yukichi Hatano, Junya Tani, Kazutoshi Mihara, Kenichi Takahashi, Atsushi Sugimura
  • Patent number: 10557115
    Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in the medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in for medium.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: February 11, 2020
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Miroslav Matev, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
  • Publication number: 20190352599
    Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in said medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in said medium.
    Type: Application
    Filed: March 26, 2019
    Publication date: November 21, 2019
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Miroslav MATEV, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
  • Publication number: 20190225700
    Abstract: Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.
    Type: Application
    Filed: August 25, 2017
    Publication date: July 25, 2019
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Yuri Koshimura, Hiroyuki Sonoda, Miroslav Matev, Shinji Kakimoto, Tsuyoshi Fukui, Yukichi Hatano
  • Patent number: 10273448
    Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in the medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in the medium.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: April 30, 2019
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Miroslav Matev, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
  • Publication number: 20190078129
    Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 14, 2019
    Inventors: Shinji KAKIMOTO, Miroslav MATEV, Tsuyoshi FUKUI, Yukichi HATANO, Junya TANI, Kazutoshi MIHARA, Kenichi TAKAHASHI, Atsushi SUGIMURA
  • Publication number: 20170233704
    Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Yuri KOSHIMURA, Miroslav MATEV, Hiroyuki SONODA
  • Publication number: 20170073633
    Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in said medium. Further provided are a medium comprising uridine and N-acethyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in said medium.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 16, 2017
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Miroslav MATEV, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani